铜川高考应届补习班哪里有哪家好(灞桥区补习复读怎么样) (今日更新中)

New York, Sept. 23 (Xinhua) -- A Chinese scientist was presented a prestigious U.S. award on Friday for the discovery of artemisinin, a drug therapy for malaria that has saved millions of lives across the globe, especially in the developing world.Pharmacologist Tu Youyou, 81, became the first scientist on the Chinese mainland to win Lasker Award, known as "America's Nobels" for their knack of gaining future recognition by the Nobel committee.Tu, a scientist at the China Academy of Chinese Medical Sciences in Beijing, pioneered a new approach to malaria treatment that has benefited hundreds of millions of people and promises to benefit many times more. By applying modern techniques and rigor to a heritage provided by 5000 years of Chinese traditional practitioners, she has delivered its riches into the 21st century."Not often in the history of clinical medicine can we celebrate a discovery that has eased the pain and distress of hundreds of millions of people and saved the lives of countless numbers of people, particularly children, in over 100 countries," Lucy Shapiro, a member of the award jury and professor of Stanford University, said while describing Tu' s discovery.Shapiro said the discovery, chemical identification, and validation of artemisinin, a highly effective anti-malarial drug, is largely due to the "scientific insight, vision and dogged determination" of Professor Tu and her team. She thought Professor Tu's work has provided the world with arguably the most important pharmaceutical intervention in the last half century."The discovery of artemisinin is a gift to mankind from traditional Chinese medicine," Tu said while receiving the award. "Continuous exploration and development of traditional medicine will, without doubt, bring more medicines to the world."

BEIJING, August 3 (Xinhuanet) -- Women who experience any form of gender-based violence are at greater risk of mental health disorders and related dysfunction and disability, according to Australian researchers Wednesday.Those who'd been through at least one form of this abuse -- which includes intimate partner violence, rape, sexual assault, or stalking -- were almost three times more likely to experience a mental health condition than those who were never victimized, according to Susan Rees, PhD of the University of New South Wales in Sydney, Australia, and her colleagues.Those who'd experienced three or four forms had an 11-fold greater risk, reported in the Aug. 3 issue of the Journal of the American Medical Association.The study "reveals a pattern of social disadvantage, disability, and impaired quality of life among women who have experienced gender-based violence," the researchers wrote.

BEIJING, Sept. 14 (Xinhuanet) -- The U.S. Food and Drug Administration (FDA) on Monday announced a recall on a drug infusion pump of Medtronic, the Associated Press reported.The recalled drug pump was called "SynchroMed II", including models of 8637-20 and 8637-40, distributed between 2004 and July 2011.Drug infusion pump was used to deliver the drugs for patients to treat chronic pain, spasms as well as other conditions.The pumps' malfunction could put patients in the risk of either recurrent or withdrawal symptoms, which could be life-threatening, FDA warned.There were 55 reported cases and one death related to the drug withdrawal, among a total 139,653 SynchroMed II pump implants worldwide, FDA notified.The problem was due to a film within the pump's battery that could stop the therapy, FDA said.Medtronic, the U.S. medical technology company based in Minneapolis, is not recommending patients to remove the pumps, but instead, encourage patients to contact their doctor if they hear the device alarm.

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."

JIANGYIN, Jiangsu, July 1 (Xinhua) -- China's manned deep-diving submersible, the Jiaolong, embarked on a journey on Friday during which it will make a 5,000-meter dive in the Pacific Ocean.During the dive, the submersible will undergo several operational tests in which it will take photos, shoot video, survey seabeds and take samples from the ocean floor, according to Jin Jiancai, deputy director of the submersible's diving test program team.The tests will be conducted in the Pacific Ocean in accordance with a contract signed between the China Ocean Mineral Resources Research & Development Association and the International Seabed Authority (ISA).The submersible is scheduled to spend 47 days at sea, according to a statement from the Ministry of Science and Technology.A submersible differs from a submarine, as it typically depends on another vessel or facility for support.The Jiaolong, designed to reach a depth of 7,000 meters, completed 17 dives in the South China Sea between May 31 and July 18 last year, reaching 3,759 meters during its deepest dive.In the year since the submersible's last dive, program team members have made several technical improvements to the submersible and its support vessel, Jin said.Jin said the program team members are "very confident" about the test.He also stressed that the test will be carried out in accordance with the provisions of the United Nations Convention on the Law of the Sea as well as the ISA's rules and regulations.The Jiaolong is the world's first manned submersible designed to reach depths of 7,000 meters below sea level, according to Xu Qinan, the submersible's chief designer.

来源：资阳报